SOLID TUMOR

This early-phase study tested a new drug called CPO-100 in 34 adults with advanced solid tumors that had not responded to at least two prior treatments. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.

This early-stage study tested a new treatment called ALPP CAR-T cells in 5 people with advanced solid tumors that had stopped responding to standard therapies. The goal was to see if the treatment was safe and to find the best dose. The study was terminated early, so results are …

This study tested a daily pill called AB-106 in people whose solid tumors had spread and carried a specific gene change (NTRK fusion). The goal was to see if the drug could shrink tumors. The trial was stopped early and included only 14 participants who had already tried other tr…

This early-stage trial tested a treatment that uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack advanced solid tumors. The goal was to check safety and side effects, but the study was stopped early after enrolling only 2 participants. Because the treat…

This early-phase study tested a lab-modified virus (ASP1012) designed to infect and kill cancer cells while alerting the immune system. It involved 15 adults with advanced solid tumors who had exhausted standard treatments. Some participants also received the immunotherapy pembro…

This study tested a combination of two drugs (rucaparib and atezolizumab) in 130 adults with advanced solid tumors that either had DNA repair defects or were sensitive to platinum chemotherapy. The goal was to see if the combination could shrink tumors. However, the trial was ter…

This early-phase study tested a new drug called ACTM-838 in 10 people with advanced solid tumors that no longer responded to standard treatments. The main goals were to check safety and find the right dose. The study was stopped early, so results are limited.

This early-stage study tested an experimental oral drug called NKT3447 in 23 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.

This trial tested an experimental drug called IBI3004 in people with advanced solid tumors that could not be removed by surgery. The study aimed to find the safest dose and check for side effects. Only 5 people took part before the study was stopped early.

This early-phase trial tested a new drug called OMX-0407 in 68 adults with advanced solid tumors that had stopped responding to other treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The study was stopped early, so results are limited.

This study tested the drug niraparib in 22 adults with advanced solid tumors (like breast, lung, or pancreatic cancer) that have a specific genetic change called a PALB2 mutation. The goal was to see if niraparib could shrink tumors or slow their growth. The study was stopped ear…

This early-phase study tested a new oral drug, BBI-825, in 19 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see how the body handles the drug, both alone and with other targeted therapies. The trial was …

This study tested a new drug called BGB-3245 in people with advanced solid tumors that had stopped responding to standard treatments. The goal was to see if the drug is safe and can shrink tumors. The trial was stopped early, and results are not yet available.

This study tested a drug called tovorafenib in people aged 12 and older with advanced solid tumors that have specific genetic changes (MAPK pathway). The goal was to see if the drug could shrink tumors. The study was stopped early, but the results may help guide future treatments…

This study tested a new drug called LY3405105 in 54 people with advanced solid tumors that had spread. The main goal was to check the drug's safety and find the right dose. The trial was stopped early, so results are limited.

This study tested a new drug called BNT142 in 73 people with advanced solid tumors that have a specific protein (CLDN6). The goal was to see if the drug is safe and how well it works. The study was stopped early, but the results help researchers understand how to treat these hard…

This early-stage study tested an experimental drug called KD033 (SAR445710) in 45 adults with advanced solid tumors that had spread. The main goal was to check the drug's safety at different doses and see how the body processes it. The study also looked for any anti-cancer effect…

This early-stage study tested an experimental virus therapy called VAXINIA (CF33-hNIS) in 66 adults with advanced solid tumors that had spread. The virus was given either directly into tumors or through a vein, alone or with the immunotherapy drug pembrolizumab. The main goal was…

This early-stage study tested a new drug called BGB-R046, alone or with another drug (tislelizumab), in 42 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The study was terminated e…

This early-phase study tested two experimental drugs, tuvusertib and PLX038, in people with advanced solid tumors that could not be cured. The goal was to find the safest dose and see if the combination could shrink tumors. Only 10 people took part before the trial was stopped ea…

This early-phase study tested a new experimental drug, BGB-A3055, alone or with another drug (tislelizumab), in people with advanced solid tumors that had spread. The main goals were to check safety, how the body handles the drug, and whether it shrinks tumors. The study was term…

This study tested an experimental drug called REC-4881 in 18 adults aged 55+ with advanced solid tumors that had changes in the AXIN1 or APC genes. The goal was to see if the drug could shrink tumors or slow their growth. The trial was stopped early, so results are limited.

This study tested a personalized treatment called GT201 for people with advanced solid tumors that had spread or come back. Doctors took immune cells from each patient's tumor, multiplied them in a lab, and infused them back after a short course of chemotherapy. The goal was to s…

This study tested a new drug called CX-072 combined with other cancer treatments in adults with solid tumors or advanced melanoma. The goal was to see if the combination could shrink tumors. However, the study was stopped early after only 3 people enrolled, so no clear results ar…

This early-phase study tested a new drug called WBC100 in 68 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the best dose. The study was stopped early, and it does not offer a cure—it aims to contro…

This early-phase study tested a personalized therapy called GT201 for people with advanced solid tumors that have spread or come back. The treatment uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are grown in a lab and given back along with chemotherapy a…

This early-stage trial tested a new drug called MRTX0902, alone or with another drug (adagrasib), in 64 people with advanced solid tumors (like lung or colon cancer) that have specific KRAS gene mutations. The main goals were to check safety and find the right dose. The study was…

This early-stage study tested a new drug called TAS2940 in 29 people with advanced solid tumors (like lung, breast, or brain cancer) that had certain genetic changes (EGFR or HER2). The goal was to find a safe dose and see if it could shrink tumors. The trial was stopped early, s…

This study tested a drug called tazemetostat in people with advanced solid tumors that have a specific genetic change (ARID1A mutation). The drug works by blocking a protein (EZH2) that helps these tumors grow. The trial aimed to see if the drug could shrink tumors or stop them f…

This early-phase study tested a new drug called LB4330 in 40 people with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to help the immune system attack cancer cells by targeting a protein called Claudin 18.2. The main goals were to…

This study tested a new type of PET scan (68Ga-MY6349) that targets a protein called Trop-2 to find thyroid cancer that has come back or spread. Researchers compared it to the standard 18F-FDG PET scan in 149 adults with different types of thyroid cancer. The goal was to see if t…